KK2269 + Docetaxel
Phase 1Recruiting 1 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Non Small Cell Lung Cancer
Trial Timeline
Jan 18, 2024 → Mar 1, 2029
NCT ID
NCT06266299About KK2269 + Docetaxel
KK2269 + Docetaxel is a phase 1 stage product being developed by Kyowa Kirin for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06266299. Target conditions include Advanced Solid Tumor, Metastatic Solid Tumor, Gastric Adenocarcinoma.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
6
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06266299 | Phase 1 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumor